Top 7 Oral Proteins and Peptides Companies Advancing Next-Generation Oral Biologic Therapies

Oral proteins and peptides are biologically active substances that are taken orally, usually as liquids, tablets, or capsules, to treat a variety of illnesses, such as gastric, metabolic, chronic, and other conditions. Since proteins and peptides are sensitive molecules that frequently struggle to survive the hostile gastrointestinal environment and reach their intended targets, delivering them has historically been a substantial difficulty. However, a new age of oral protein and peptide therapeutics has been made possible by the most recent developments in drug delivery technology. The industry’s dedication to overcoming these challenges has been demonstrated by the FDA’s approval of a number of novel oral protein and peptide medications.

In addition to providing patients with a more practical and comfortable option than injectable or intravenous administration, these novel medicines have the potential to completely transform the treatment of a variety of illnesses, including diabetes and hormone shortages. As a result, the pharmaceutical industry is a fast changing landscape that is primarily motivated by the prospect of increased bioavailability, better patient compliance, and the opportunity to treat a wide range of unmet medical needs.

Given their greater absorption rates and efficacy, which appeals to customers looking for rapid results, oral peptides lead the industry. They are becoming more and more popular among athletes and fitness enthusiasts owing to their widespread use in supplements targeted at weight management and muscle rehabilitation.

On the other hand, oral proteins are becoming a popular substitute, particularly with the growth of plant-based protein sources as they are attracting a growing number of individuals who are concerned about their health.

Fortune Business Insights estimates the market for oral proteins and peptides to grow from USD 3.36 billion in 2025 to USD 9.17 billion by 2034, with a significant CAGR of 11.03% over the forecast period.

Fortune Business Insights Discloses its Top 7 Oral Proteins and Peptides Companies:

1. Novo Nordisk

One of the top 7 oral proteins and peptides companies, Novo Nordisk was established in 1923 with its headquarters in Denmark. Diabetes treatment, obesity, uncommon disorders, and biopharmaceuticals with a focus on proteins and peptides comprise the core business of the company. The firm leads the world in GLP-1 and insulin treatments. With Rybelsus (oral semaglutide), the first oral GLP-1 approved for type 2 diabetes, the firm led the way in the development of commercial oral peptides. It overcomes gastrointestinal breakdown by using SNAC absorption-enhancer technology.

2. Chiesi Group

Chiesi Group was founded in 1935 and is headquartered in Italy. It has its core business in R&D and production of pharmaceuticals in respiratory, uncommon disorders, and special care. The firm is a B Corp certified international pharmaceutical group with a focus on biotech and inhalation medicines. The firm specializes in uncommon disorders and is actively researching oral peptide delivery, particularly for protein-based therapy and enzyme replacement, where injections are the standard. Chiesi Group acquired Amryt Pharma in January 2023. Mycapssa (octreotide capsules), an oral formulation of a peptide analog (octreotide) used to treat the rare condition acromegaly, was a crucial part of this acquisition.

3. EnteraBio Ltd.

EnteraBio Ltd. was established in 2010 with its headquarters in Israel. The firm deals in oral delivery of big molecules, with an emphasis on proteins and peptides. Oral biologic technologies are the focus of this clinical-stage biotech company. The firm uses their N-TabTM technology, which combines protease inhibitors and absorption enhancers, to create oral versions of injectable peptides. At the 2025 ESPEN Congress, EnterBio presented favorable PK results for its first-in-class oral GLP-2 pill.

4. Oramed

Another name in top 7 oral proteins and peptides companies, Oramed was established in 2006 and is headquartered in the U.S. Oral administration of injectable medications with an emphasis on proteins and peptides is the main business. To safeguard peptides in the gut, the firm created the POD^TM oral protein delivery technology, which combines protease inhibitors and absorption enhancers.

5. Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. was founded in 2006 with its headquarters in the U.S. It has its expertise in oral peptide-based medication development and discovery. Unlike most biologics, Protagonist creates oral stable peptides that are resistant to digestion. JNJ-2113, an oral IL-23 receptor antagonist peptide in Phase 3 with Johnson & Johnson for ulcerative colitis and psoriasis, is the company’s lead asset. Moreover, another obesity-focused oral peptide program was added to the competitive pipeline in June 2025 when Protagonist nominated PN-477 as an injectable and oral peptide development candidate.

6. Biocon

Biocon was established in 1978 and is headquartered in India. Biopharmaceuticals, biosimilars, research services, and generics comprise the core business of the company. Leading Indian biopharmaceutical company Biocon is a significant competitor in the global market. The firm is involved in oral insulin research and development and creates reasonably priced biologics. Its top oral insulin candidate, IN-105 (Tregopil), has finished Phase 2/3 trails in India and improves intestine absorption through lipid-based administration. The objective is to replace type 2 diabetes injections with a room-temperature oral insulin tablet.

7. Rani Therapeutics

Rani Therapeutics was founded in 2012 with its headquarters in the U.S., with its primary business in oral administration of biologics using robotic pill technology. New preclinical semaglutide results demonstrating effective oral semaglutide delivery using the RaniPill capsule were published by Rani Therapeutics in February 2025.

Preference for Oral Administration Is Set To Present Lucrative Opportunity For Oral Proteins And Peptides

The market for oral proteins and peptides is gradually evolving from a specialized area of invention to a revolutionary force in contemporary medicine. Oral administration forms are gaining popularity owing to their convenience, better adherence, and potential to replace traditional injectable medicines as healthcare systems place a greater emphasis on patient-centric approaches. Long standing issues with oral bioavailability are being addressed by developments in drug delivery methods, such as improved permeability systems and enzyme protection mechanisms. Simultaneously, increasing investments from biotechnology and pharmaceutical businesses are speeding up the development of reliable pipelines, encouraging innovation in both developed and developing markets. In conclusion, oral biologics are expected to be crucial in determining the direction of medication delivery and therapeutic treatment globally as innovation continues to transform the pharmaceutical industry.